Brazil’s National Health Surveillance Agency (Anvisa) has approved a new medication for the treatment of diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin lymphoma.
The regulatory decision, announced on Monday, targets patients who have experienced disease relapse or failed to respond to initial therapy and are not candidates for bone marrow transplantation.
Similarly, French biotech firm Abivax saw its shares surge 36% following positive clinical trial data for its lead candidate, highlighting investor appetite for breakthrough treatments.
The drug utilizes the body’s immune system to target cancer cells, marking a significant expansion of therapeutic options in the Brazilian oncology market.
The approval aligns with a broader trend of regulatory momentum in the biotechnology sector, where novel immunotherapies are gaining traction across global markets.
In Europe, the European Commission recently granted marketing authorization for Wegovy in tablet form, underscoring the accelerating pace of drug approvals for complex conditions.
Similarly, French biotech firm Abivax saw its shares surge 36% following positive clinical trial data for its lead candidate, highlighting investor appetite for breakthrough treatments.